Regorafenib Post-marketing Surveillance
NCT01843400
·
clinicaltrials.gov ↗
COMPLETED
Status
1301
Enrollment
INDUSTRY
Sponsor class
Conditions
Colorectal Neoplasms
Interventions
DRUG:
Regorafenib (Stivarga, BAY73-4506)
Sponsor
Bayer